Acute Respiratory Distress Syndrome Clinical Trial
Official title:
Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS
Mortality in Acute Respiratory Distress Syndrome is high (40 to 60 %). Protective mechanical
ventilation, until 2010, was the cornerstone of the ARDS therapeutic strategies. Recently, a
prospective multicenter study demonstrates that a 48h continuous infusion of neuromuscular
blocking agents (NMBA) have a positive impact on mortality of ARDS patients. (Papazian et
al. ACURASYS Study. NEJM 2010; 363:1107-16). The mechanisms through which NMBAs could
improve survival remain speculative. They are as follows:
- reduction of the consumption of oxygen linked to ventilatory workload;
- increase of chest wall compliance improving mechanical ventilation during ARDS and
better adaptation to the protective ventilation strategy;
- anti-inflammatory effect contributing to a reduction in pulmonary inflammation and
improvement in oxygenation,
- reduction of the variations of transpulmonary pressure (TPP) by the way of better
synchronisation between patient and the ventilator.
The use of NMBA could also reduce the ventilator induced lung injury by a better control of
TPP.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |